Morgan Stanley weighs in on Eli Lilly (LLY) following Cigna GLP-1 news
Tweet Send to a Friend
Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,133.00 price target on Eli Lilly (NYSE: LLY) after Cigna/Evernorth ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
